TY  - JOUR
AU  - Hortobagyi, Gabriel N
AU  - Stemmer, Salomon M
AU  - Burris, Howard A
AU  - Yap, Yoon-Sim
AU  - Sonke, Gabe S
AU  - Paluch-Shimon, Shani
AU  - Campone, Mario
AU  - Blackwell, Kimberly L
AU  - André, Fabrice
AU  - Winer, Eric P
AU  - Janni, Wolfgang
AU  - Verma, Sunil
AU  - Conte, Pierfranco
AU  - Arteaga, Carlos L
AU  - Cameron, David A
AU  - Petrakova, Katarina
AU  - Hart, Lowell L
AU  - Villanueva, Cristian
AU  - Chan, Arlene
AU  - Jakobsen, Erik
AU  - Nusch, Arnd
AU  - Burdaeva, Olga
AU  - Grischke, Eva-Maria
AU  - Alba, Emilio
AU  - Wist, Erik
AU  - Marschner, Norbert
AU  - Favret, Anne M
AU  - Yardley, Denise
AU  - Bachelot, Thomas
AU  - Tseng, Ling-Ming
AU  - Blau, Sibel
AU  - Xuan, Fengjuan
AU  - Souami, Farida
AU  - Miller, Michelle
AU  - Germa, Caroline
AU  - Hirawat, Samit
AU  - O'Shaughnessy, Joyce
PY  - 2016
DO  - 10.1056/NEJMoa1609709
UR  - http://hdl.handle.net/10668/10515
T2  - The New England journal of medicine
AB  - The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Letrozole
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Nitriles
KW  - Purines
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Triazoles
TI  - Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
TY  - research article
VL  - 375
ER  -